Alina, was then working as a teacher at a secondary school in Kajang, Selangor. Initially, she thought her condition was due ...

The myasthenia gravis treatment market is anticipated to grow at a CAGR of 7.14% from US$1.973 billion in 2025 to US$2.785 ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

she was diagnosed with myasthenia gravis (MG), a rare autoimmune disease. “I didn’t know what to feel – relieved because I finally knew the cause or afraid because I had never even heard of the ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Watchers of the percolating myasthenia gravis space are waiting eagerly for data from Dianthus Therapeutics Inc.’s phase II Magic study testing DNTH-103, an active C1s inhibitor, compared to placebo ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

The investment objective of the VT Gravis UK Infrastructure Income Fund is to generate income and preserve capital with potential for capital growth. The sub-fund will aim to meet its objectives by ...

flare-ups of intestinal diseases, such as ulcerative colitis flare-ups of nervous system disorders, such as multiple sclerosis or myasthenia gravis certain leukemias and lymphomas, which are blood ...